What generic drugs of Anamorelin are currently on the market?

Anamorelin (Anamorelin) is an innovative drug that has attracted much attention. It was originally developed by Japan's Ono Pharmaceutical and marketed in Japan under the trade name "Adlumiz" for improving cancer-related cachexia (Cancer Cachexia). Cachexia is a metabolic syndrome that is closely related to tumor progression. Patients show significant weight loss, muscle loss, and loss of appetite. In severe cases, it may even affect the tolerance of anti-cancer treatment and quality of life. Anamorelin brings new treatment ideas to this clinical problem with its unique mechanism of action. The drug selectively activates the ghrelin receptor (GHS-R1a), stimulates the appetite center of the hypothalamus, enhances the patient's desire to eat, and promotes the release of growth hormone (GH) and insulin-like growth factor (IGF-1) to help patients regain physical strength and weight.

Currently, the global promotion of anamorelin is gradually expanding, but it has not yet been officially approved for marketing in mainland China, so some patients will obtain the drug through overseas channels. In Japan, South Korea, Laos, Bangladesh and other countries, multiple generic versions of anamulin have been launched. Among them, the generic drug Anamorelin produced by Laos Pharmaceutical Factory is more common. Its ingredients are consistent with the original drug and its pharmacological activity is the same. It is suitable for improving weight loss and malnutrition caused by cancer. The common specification of this medicine is 50mg*100 tablets. Each box is priced at about RMB 2,000. The price will fluctuate slightly due to exchange rate changes and channel differences. Compared with original drugs, which can easily cost tens of thousands of yuan, generic drugs clearly have a price advantage.

In terms of drug quality, some overseas pharmaceutical factories have passed internationalGMP certification, and the production process strictly follows international drug standards, thus ensuring a high degree of consistency with the original drugs in terms of efficacy and safety. In recent years, as international drug patent protection gradually expires, more and more emerging pharmaceutical companies have invested in the research and development and production of generic drugs of anamorelin, which not only expands market accessibility, but also injects new competitive power into the field of cancer supportive care.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC4677053/